GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Agilent Technologies Inc (NYSE:A) » Definitions » Intrinsic Value: Projected FCF
中文

Agilent Technologies (Agilent Technologies) Intrinsic Value: Projected FCF

: $66.20 (As of Today)
View and export this data going back to 1999. Start your Free Trial

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-24), Agilent Technologies's Intrinsic Value: Projected FCF is $66.20. The stock price of Agilent Technologies is $136.98. Therefore, Agilent Technologies's Price-to-Intrinsic-Value-Projected-FCF of today is 2.1.

The historical rank and industry rank for Agilent Technologies's Intrinsic Value: Projected FCF or its related term are showing as below:

A' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.08   Med: 2.01   Max: 3.15
Current: 2.07

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Agilent Technologies was 3.15. The lowest was 1.08. And the median was 2.01.

A's Price-to-Projected-FCF is ranked worse than
68.75% of 96 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.59 vs A: 2.07

Agilent Technologies Intrinsic Value: Projected FCF Historical Data

The historical data trend for Agilent Technologies's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agilent Technologies Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.79 43.01 53.23 59.40 63.96

Agilent Technologies Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.14 63.30 62.23 63.96 66.20

Competitive Comparison

For the Diagnostics & Research subindustry, Agilent Technologies's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agilent Technologies Price-to-Projected-FCF Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Agilent Technologies's Price-to-Projected-FCF falls into.



Agilent Technologies Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Agilent Technologies's Free Cash Flow(6 year avg) = $1,082.24.

Agilent Technologies's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Jan24)*0.8)/Shares Outstanding (Diluted Average)
=(13.410827369688*1082.24+6188*0.8)/294.000
=66.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agilent Technologies  (NYSE:A) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Agilent Technologies's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=136.98/66.204536777453
=2.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agilent Technologies Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Agilent Technologies's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Agilent Technologies (Agilent Technologies) Business Description

Traded in Other Exchanges
Address
5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.
Executives
Philip Binns officer: Senior Vice President 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Rodney Gonsalves officer: V.P., Corporate Controller 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Henrik Ancher-jensen officer: Sr. Vice President 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Michael R. Mcmullen officer: CEO and President 5301 STEVENS CREEK BLVD., MS 1A-LC, SANTA CLARA CA 95051
George A Scangos director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Mikael Dolsten director 5 GIRALDA FARMS, MADISON NJ 07940
Mala Anand director C/O COTIVITI HOLDINGS, INC., 115 PERIMETER CENTER PLACE, SUITE 700, ATLANTA GA 30346
Sue H. Rataj director C/O CABOT CORPORATION, TWO SEAPORT LANE, SUITE 1300, BOSTON MA 02210
Dow R Wilson director VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Boon Hwee Koh director C/O AGILENT TECHNOLOGIES, 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Heidi Fields director 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Hans Edgar Bishop director 60 WEST 66TH STREET, 26A, NEW YORK NY 10023
Daniel K Podolsky director 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Padraig Mcdonnell officer: Senior Vice President 5301 STEVENS CREEK BLVD, SANTA CLARA CA 95051